Functional changes in cerebrovasculature, including diminished CBF have also been correlated with tau pathology in primary tauopathies such as progressive supranuclear palsy (PSP) and frontotemporal dementia with parkinsonism‐17 (FTDP‐17) where amyloid deposition is not apparent,12, 13, 14, 15 further suggesting a dynamic interplay between cerebrovascular dysfunction and AD‐related pathologies in accelerating disease progression. This evidence concerns the gene MAPT and tauopathy.